The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

69 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.EBI
Arena Pharmaceuticals
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DPEBI
Novartis Institutes For Biomedical Research
Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat.EBI
Arena Pharmaceuticals
A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques.EBI
Amgen
Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP.EBI
Amgen
Prostanoid receptor EP2 as a therapeutic target.EBI
Emory University
Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.EBI
Pfizer
Isoquinoline derivatives as potent CRTH2 antagonists: design, synthesis and SAR.EBI
Taisho Pharmaceutical
Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.EBI
Novartis Institutes For Biomedical Research
Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.EBI
Actelion Pharmaceuticals
Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.EBI
Actelion Pharmaceuticals
Understanding DP receptor antagonism using a CoMSIA approach.EBI
Sanofi Aventis Us
Diazine indole acetic acids as potent, selective, and orally bioavailable antagonists of chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) for the treatment of allergic inflammatory diseases.EBI
Pfizer
Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.EBI
Actelion Pharmaceuticals
Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists.EBI
TBA
Isoquinoline derivatives as potent CRTH2 receptor antagonists: synthesis and SAR.EBI
Taisho Pharmaceutical
Benzodiazepinone Derivatives as CRTH2 Antagonists.EBI
TBA
Discovery and optimization of CRTH2 and DP dual antagonists.EBI
Amgen
Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.EBI
Merck Frosst Centre For Therapeutic Research
Comparison between two classes of selective EP(3) antagonists and their biological activities.EBI
Merck Frosst Centre For Therapeutic Research
Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.EBI
Fujisawa Pharmaceutical
Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.EBI
Merck Frosst Centre For Therapeutic Research
Optimization of phenylacetic acid derivatives for balanced CRTH2 and DP dual antagonists.EBI
Amgen
Discovery of AMG 853, a CRTH2 and DP Dual Antagonist.EBI
TBA
Discovery of novel and potent CRTH2 antagonists.EBI
Astellas Pharma
Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism.EBI
Amgen
Discovery of new orally active prostaglandin D2 receptor antagonists.EBI
Ono Pharmaceutical
Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis.EBI
Amira Pharmaceuticals
Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.EBI
Merck Serono
New indole amide derivatives as potent CRTH2 receptor antagonists.EBI
Merck Frosst
Thienopyrrole acetic acids as antagonists of the CRTH2 receptor.EBI
Abbott Laboratories
Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.EBI
Amira Pharmaceuticals
Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases.EBI
Merck Frosst Centre For Therapeutic Research
Azaindoles as potent CRTH2 receptor antagonists.EBI
Merck Frosst Centre For Therapeutic Research
Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore.EBI
Merck Frosst Centre For Therapeutic Research
Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain.EBI
Merck Frosst Canada
Exploration of SAR features by modifications of thiazoleacetic acids as CRTH2 antagonists.EBI
7Tm Pharma
Tetrahydroquinoline derivatives as CRTH2 antagonists.EBI
Amgen
Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2.EBI
7Tm Pharma
The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.EBI
Merck Frosst Centre For Therapeutic Research
Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis.EBI
Amira Pharmaceuticals
7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.EBI
Novartis Institutes Of Biomedical Research
Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists.EBI
Glaxosmithkline
Discovery of potent and selective DP1 receptor antagonists in the azaindole series.EBI
Merck Frosst Centre For Therapeutic Research
Highly functionalized 7-azaindoles as selective PPAR gamma modulators.EBI
Merck Research Laboratories
The many roles for fluorine in medicinal chemistry.EBI
Merck Research Laboratories
2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.EBI
Novartis Institutes Of Biomedical Research
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).EBI
Merck Frosst Canada
Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits.EBI
7Tm Pharma
Identification of an indole series of prostaglandin D2 receptor antagonists.EBI
Merck Frosst Canada
Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2.EBI
Oxagen
Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4.EBI
Fujisawa Pharmaceutical
Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists.EBI
Fujisawa Pharmaceutical
Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist.EBI
7Tm Pharma
Discovery of orally active prostaglandin D2 receptor antagonists.EBI
Minase Research Institute
Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 2. 6,6-Dimethylbicyclo[3.1.1]heptane derivatives.EBI
Shionogi
Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 1. Bicyclo[2.2.1]heptane derivatives.EBI
Shionogi
Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor.EBI
Merck Frosst Centre For Therapeutic Research
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis.EBI
Procter & Gamble Pharmaceuticals
Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).EBI
Bayer
Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry.EBI
Merck Frosst Canada
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor.EBI
Procter And Gamble Pharmaceuticals
New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor.EBI
Merck Frosst Centre For Therapeutic Research
Bicyclo[2.2.1]heptane and 6,6-dimethylbicyclo[3.1.1]heptane derivatives: orally active, potent, and selective prostaglandin D2 receptor antagonists.EBI
Shionogi
Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition.EBI
Merck
Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EPEBI
Glaxosmithkline
Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.EBI
Merck